12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

ISIS-TTRRx regulatory update

FDA granted Fast Track designation to Isis' ISIS-TTRRx to treat familial amyloid polyneuropathy. Isis plans to start a Phase II/III trial of the transthyretin (TTR) antisense inhibitor this month....

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >